New eye drug shows promise for Diabetes-Related vision loss
Disease control
Completed
This phase 2a trial tested a new biologic drug called AG-73305, given as an injection into the eye, in 25 adults with diabetic macular edema (DME), a common cause of vision loss in people with diabetes. The study aimed to check the drug's safety and how well it works over 6 month…
Phase: PHASE2 • Sponsor: Allgenesis Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC